TetraLogic Pharmaceuticals Corporation (NASDAQ:TLOG) has climbed 5.9% in the past week and advanced 22.51% in the last 4 weeks. In the past week, the company has outperformed the S&P 500 by 7.17% and the outperformance has advanced to 21.39% for the last 4 weeks period.
TetraLogic Pharmaceuticals Corporation (NASDAQ:TLOG): During Fridays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $0.28 and $0.28 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $0.34. The buying momentum continued till the end and the stock did not give up its gains. It closed at $0.31, notching a gain of 11.64% for the day. The total traded volume was 1,852,479 . The stock had closed at $0.28 on the previous day.
The company shares have dropped -86.82% from its 1 Year high price. On Jul 1, 2015, the shares registered one year high at $3.75 and the one year low was seen on Feb 25, 2016. The 50-Day Moving Average price is $0.29 and the 200 Day Moving Average price is recorded at $0.48.
On the companys insider trading activities, Pecora Andrew L, director of Tetralogic Pharmaceuticals Corp had purchased 50,000 shares on July 10, 2015 in a transaction. The price per share was $2.66 and the total amount of the disclosed transaction was $133,000.The Insider information was disclosed with the Securities and Exchange Commission in a Form 4 filing. This information is based on open market transaction at the market prices.
Currently the company Insiders own 51.6% of TetraLogic Pharmaceuticals Corporation shares according to the proxy statements. Institutional Investors own 3.59% of TetraLogic Pharmaceuticals Corporation shares. During last six month period, the net percent change held by insiders has seen a change of -52.32%.
TetraLogic Pharmaceuticals Corporation is a clinical-stage biopharmaceutical company engaged in discovering and developing small molecule therapeutics in oncology and infectious diseases. The Company has two clinical-stage product candidates: birinapant and suberohydroxamic acid 4-methoxycarbonyl phenyl ester (SHAPE). Birinapant is a small molecule therapeutic that mimics second mitochondrial activator of caspases (SMAC-mimetic). Birinapant is in a Phase II clinical trial for the treatment of myelodysplastic syndromes (MDS), a Phase I/II clinical trial for third-line ovarian cancer and a Phase I clinical trial for the treatment of chronic human hepatitis B virus (HBV). The Company has completed a Phase I/II clinical trial of birinapant in acute myeloid leukemia (AML), MDS and acute lymphocytic leukemia (ALL). SHAPE is a histone deacetylase (HDAC) inhibitor for topical use for the treatment of early-stage cutaneous T-cell lymphoma (CTCL) and is in Phase II clinical trial stage.